Bevacizumab Injection Syringes Recalled for Sterility Assurance Concerns
Fagron Compounding Services is recalling 109,320 syringes of bevacizumab (Avastin) Injection due to lack of assurance of sterility. The product was distributed nationwide with multiple lot numbers and expiration dates through December 2025.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of sterile injectable medication due to lack of sterility assurance constitutes a risk-of-harm product. While no illnesses or injuries have been reported, sterility failures in injectable medications pose potential for serious infection. This fits the High severity criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Fagron Compounding Services is recalling approximately 109,320 sterile single-dose syringes of bevacizumab (Avastin) Injection, 1.25mg/0.05mL. The affected product was distributed nationwide with multiple lot numbers and expiration dates ranging from August 2025 through December 2025.
The FDA Class II recall was initiated due to lack of assurance of sterility in the affected syringes.
Patients and healthcare providers who have received or possess syringes from the affected lot numbers should consult their healthcare provider regarding this recall. Syringes from the affected lots should not be used.
The recalled product
- Product
- bevacizumab (Avastin) Injection, 1.25mg/0.05mL (0.12 mL Fill), Sterile Single-Dose Syringe, Fagron Sterile Services, 8710 E 34th St N. Wichita, KS 67226
- Manufacturer
- Fagron Compounding Services
- Category
- Drug — Injectable
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: C274-000044756
- C274-000044757
- Exp 8-30-2025
- C274-000044832
- C274-000044833
- Exp 9-4-2025
- C274-000044882
- C274-000044883
- Exp 9-6-2025
- C274-000044972
- Exp 9-8-2025
- C274-000045004
- C274-000045005
- Exp 9-18-2025 C274-000045108
- exp. date 9-13-2025 C274-000045109
- exp. date 9-13-2025 C274-000045136
- exp. date 9-14-2025 C274-000045137
- exp. date 9-14-2025 C274-000045289
- exp. date 9-20-2025 C274-000045290
- exp. date 9-20-2025 C274-000045350
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27